Karuna Therapeutics, Inc. and GFB, LLC, assignee of the Goldfinch Bio assignment estate, today announced their entry into an exclusive license agreement under which Karuna will obtain global ...

Karuna Therapeutics, Inc. Unaudited Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended Year Ended December 31, December 31, ...

Karuna Therapeutics focuses on therapies to treat neurological conditions. The stock is up more than 52% over the past year. The company has, as of the fourth quarter, $1.1 billion in cash, it said.

Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter: These 12 analysts have an average price target of $281.25 versus the current price of ...

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today ...

Shares of Karuna Therapeutics Inc. more than tripled (up 254%) in active trading, to lift the biopharmaceutical company's market capitalization to well above $1 billion, after a phase 2 trial of ...

The team behind Karuna Therapeutics, the Boston biotech that was bought by drug giant Bristol Myers Squibb in a $14 billion deal in December, launched another company on Tuesday called Seaport ...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the pote ...

Drugmaker Bristol Myers BMY-0.83%decrease; red down pointing triangle Squibb reached a deal to buy neuroscience-drug developer Karuna Therapeutics for $14 billion. Under the terms, Bristol would ...

Karuna Therapeutics. Karuna Therapeutics is a clinical-stage biotech headquartered in Boston, MA, founded back in July 2009 by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn.The company ...

Over the past 3 months, 8 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal.